financetom
Business
financetom
/
Business
/
India expects $7.4 billion spending on fighter jet engines over next decade
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India expects $7.4 billion spending on fighter jet engines over next decade
Oct 17, 2025 5:23 AM

NEW DELHI, Oct 17 (Reuters) - India expects to spend

about 654 billion rupees ($7.44 billion) to buy engines for

fighter aircraft that are under development until 2035,

according to estimates shared on Friday by a defence official

who leads the efforts to build a home-grown engine.

The country will require about 1,100 engines for a variety

of fighter jet programmes that are progressing through various

stages, said S. V. Ramana Murthy, director of India's Gas

Turbine Research Establishment, a state-run defence laboratory.

India's decades-old programme to power its light combat

Tejas jets with home-grown Kaveri engine has yet to take off due

to technical shortcomings.

"There is a need to work on mission mode to create an

ecosystem for indigenous fighter engine," Murthy said at an

event in New Delhi, adding that the country needed

infrastructure such as a high-altitude testing facility, along

with an industrial base.

He also said that a derivative of the Kaveri engine can be

used for a home-grown unmanned combat aerial vehicle.

Murthy is heading the efforts to co-develop an engine with

an international partner to power India's first 5th generation

stealth fighter aircraft, for which France's Safran,

Britain's Rolls-Royce and U.S. General Electric

have shown interest.

A prototype of the fighter, known as the Advanced Medium

Combat Aircraft, is expected to roll out in 2028, Indian

officials have previously said.

It is the first fighter aircraft for which bids would also

be open to private firms, the government has said, in order to

reduce pressure on Indian state-owned warplane maker Hindustan

Aeronautics Ltd, which makes most of India's military

aircraft.

Prime Minister Narendra Modi's government has sought to

boost India's manufacturing capacity for defence equipment and

invited weapon makers to set up units by partnering with Indian

firms.

($1 = 87.9462 Indian rupees)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exclusive-Chinese buyers cancel or postpone Australian wheat buys amid global oversupply
Exclusive-Chinese buyers cancel or postpone Australian wheat buys amid global oversupply
Mar 14, 2024
(Restores dropped 'to' in paragraph 2) By Naveen Thukral SINGAPORE (Reuters) -Chinese wheat importers have cancelled or postponed about one million metric tons of Australian wheat imports, trade sources with direct knowledge of the deals said, as growing world stockpiles drag down prices. The moves come after the U.S. government reported cancellation of more than 500,000 metric tons of U.S....
Solidion Technology to Raise $3.9 Million in Private Placement of Securities
Solidion Technology to Raise $3.9 Million in Private Placement of Securities
Mar 14, 2024
03:42 AM EDT, 03/14/2024 (MT Newswires) -- Solidion Technology ( STI ) said late Wednesday it has agreed to sell about $3.9 million worth of securities in a private placement to institutional investors. The company is offering a total of 5.1 million units and pre-funded units in the private placement. Each unit and pre-funded unit will consist of one common...
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
Mar 14, 2024
March 14 (Reuters) - Drugmaker AstraZeneca said on Thursday it would acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio. Amolyt, backed by investors including Danish drugmaker Novo Nordisk's parent firm Novo Holdings and EQT Life Sciences, is currently in the late-stage development of a therapy for hypoparathyroidism....
AstraZeneca to buy Amolyt Pharma for $1.05 billion to boost rare diseases portfolio
AstraZeneca to buy Amolyt Pharma for $1.05 billion to boost rare diseases portfolio
Mar 14, 2024
(Reuters) - Drugmaker AstraZeneca said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved